Ensemble discovers and develops small molecule therapies for cancer and other serious diseases. The company is aggressively applying its proprietary drug discovery platform to develop novel small molecules therapies against well-validated, but challenging disease targets that are not adequately treated by conventional small molecules or antibodies. Ensemble’s lead oncology program is focused on the immune checkpoint target IDO, which is implicated in a variety of cancers. The company also has a number of other development programs in oncology, including deubiquitinase (DUB) antagonists. Ensemble was founded in 2004 by renowned Harvard Professor David R. Liu, Ph.D., and is backed by a blue-chip investor syndicate. For more information, visit www.ensembletx.com